New Campaign from Arcutis Aims to Educate, Raise Awareness, and Provide Encouragement for Those Living with Seborrheic Dermatitis
25 Setembro 2023 - 10:00AM
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT), an early
commercial-stage company focused on developing meaningful
innovations in immuno-dermatology, today announced the launch of an
educational campaign designed to elevate understanding, connection,
and encouragement for those living with seborrheic dermatitis, or
Seb Derm for short. The campaign, Clearing Up Seb Derm, features
expert advice from leading dermatologists and personal stories from
individuals living with seborrheic dermatitis.
Clearing Up Seb Derm sheds light on the lack of information and
understanding of seborrheic dermatitis, and how this condition has
an impact beyond the skin, affecting people’s everyday lives. The
campaign also aims to raise awareness that Seb Derm symptoms can
vary from person to person, may look different across body areas
and skin tones, and can sometimes be confused with other skin
conditions.
“Seborrheic dermatitis is a common inflammatory skin condition
that affects an estimated 10 million Americans. Seborrheic
dermatitis can affect anyone, and for Black/African Americans
patients, it is the third most common skin condition seen in the
dermatology clinic,” said Andrew Alexis, M.D., Vice-Chair for
Diversity and Inclusion for the Department of Dermatology and
Dermatologist at Weill Cornell Medicine, who serves as a consultant
for Arcutis Biotherapeutics. “In richly pigmented skin, seborrheic
dermatitis can present differently than in lightly pigmented skin.
For example, patients with skin of color often present with lighter
colored patches on the cheeks, eyebrows, or hairline with or
without visible redness or scaling. This campaign can help raise
awareness and understanding of Seb Derm across various skin
types.”
Many people with Seb Derm report that the condition has a
significant impact on their appearance, personal hygiene routine,
anxiety levels, embarrassment, clothing choices, and quality of
sleep. Despite the significant impact on a person’s life, a 2022
online Harris Poll survey of over 300 adults living with Seb Derm
showed that 63% of people didn’t think their symptoms were severe
enough to warrant medical attention.
“There is a common misconception that Seb Derm is a hygiene
issue, but in actuality, it’s a real medical condition that can
significantly impact an individual’s quality of life. People who
experience seborrheic dermatitis are often reluctant and
embarrassed to discuss their symptoms and to seek care,” said Geeta
Yadav, M.D., and Founder of FACET Dermatology. “The survey found
that on average, it takes individuals 3.6 years from the appearance
of symptoms to visit a healthcare provider. We have options to help
individuals with Seb Derm, but the first step is to visit a
healthcare provider who can provide a clinical diagnosis and
treatment plan.”
As someone living with Seb Derm, Christina Sims understands the
embarrassment this skin condition can cause, and wants people to
remember they’re not alone.
“I waited about six months before I went to see my dermatologist
about my symptoms because I could not find information online.
After my diagnosis, I felt so alone and embarrassed. Through
sharing my story online, I was able to find and connect with other
people experiencing the same thing,” said Christina, a personal
brand and marketing strategist, and entrepreneur. “That’s why I’ve
partnered with Arcutis for this campaign. We aim to provide
educational resources about Seb Derm so people can feel empowered
to see their healthcare provider sooner, as well as encourage those
suffering from Seb Derm to connect with each other through a site
specifically designed to help build a sense of community.”
“Seb Derm is a highly visible skin condition, and often appears
on the face, where it’s difficult to hide symptoms like flaking and
redness. The associated social stigma that comes with Seb Derm is
an added challenge for individuals to take the initiative to seek
diagnosis and care,” said Patrick Burnett, M.D., Ph.D., FAAD, Chief
Medical Officer at Arcutis. “Through Clearing Up Seb Derm, Arcutis
hopes to encourage people to speak with their healthcare providers
sooner, rather than later, so they can get the appropriate
treatment, care, and support that they need.”
A Media Snippet accompanying this announcement is available by
clicking on the image or link below:
For more information about this initiative, visit
http://www.clearingupsebderm.com/.
About ArcutisArcutis Biotherapeutics, Inc.
(Nasdaq: ARQT) is a medical dermatology company that champions
meaningful innovation to address the urgent needs of individuals
living with immune-mediated dermatological diseases and conditions.
With a commitment to solving the most persistent patient challenges
in dermatology, Arcutis has a growing portfolio that harnesses our
unique dermatology development platform coupled with our
dermatology expertise to build differentiated therapies against
biologically validated targets. Arcutis’ dermatology development
platform includes a robust pipeline with multiple clinical programs
for a range of inflammatory dermatological conditions including
scalp and body psoriasis, atopic dermatitis, seborrheic dermatitis,
and alopecia areata. For more information,
visit www.arcutis.com or follow Arcutis on LinkedIn,
Facebook, and X.
Contacts:MediaAmanda Sheldon,
Head of Corporate Communicationsasheldon@arcutis.com
InvestorsEric McIntyre, Head of Investor
Relationsemcintyre@arcutis.com
Arcutis Biotherapeutics (NASDAQ:ARQT)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Arcutis Biotherapeutics (NASDAQ:ARQT)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024